3510 completed, 635 terminated, 228 recruiting, 165 active not recruiting. 1415 Phase 1, 1224 Phase 2, 889 Phase 3, 449 Phase 4, 273 Not applicable.
Follow Pfizer: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Korea Post Marketing Surveillance (PMS) Study of Talzenna® Talzenna - Breast Neoplasms | Withdrawn | Pfizer | 2027-06-01 | 2026-09-14 | ||
| Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Pfizer | 90 | 2027-05-01 | 2026-09-16 |
| A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea Rimegepant sulfate - Migraine With or Without Aura | Not yet recruiting | Pfizer | 3000 | 2027-03-01 | 2026-09-25 | |
| A Study to Learn More About Tukysa Once it is Out in the Korean Market HER2-positive Locally Advanced Unresectable, Metastatic Breast Cancer | Not yet recruiting | Pfizer | 600 | 2027-01-01 | 2025-11-17 | |
| HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV Elranatamab (Elra) - Plasmablastic Lymphoma, HIV | Phase 1 | Not yet recruiting | University of Illinois at Chicago | 17 | 2026-12-01 | 2026-10-06 |
| A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer Atirmociclib, giredestrant, Atirmociclib placebo - Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | Phase 3 | Not yet recruiting | Pfizer | 3800 | 2026-12-01 | 2026-10-22 |
| A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Not yet recruiting | Pfizer | 54 | 2026-11-19 | 2026-10-01 |
| A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Afimkibart, Placebo - Moderately to Severely Active Ulcerative Colitis | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 350 | 2026-11-15 | 2026-09-29 |
| Tucatinib Continuation Study tucatinib - HER2-positive Breast Cancer, Cervical Cancer | Phase 4 | Not yet recruiting | Pfizer | 175 | 2026-11-06 | 2026-08-28 |
| A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity PF-08653944 - Overweight, Obesity | Phase 1 | Not yet recruiting | Pfizer | 16 | 2026-11-01 | 2026-10-13 |
| Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva Tisotumab Vedotin - Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer | Phase 2 | Not yet recruiting | GOG Foundation | 28 | 2026-11-01 | 2026-06-29 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity Placebo, PF-08656795 - Overweight and/or Obesity | Phase 1 | Not yet recruiting | Pfizer | 150 | 2026-10-30 | 2026-10-15 |
| A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults RSVpreF (Regimen A), RSVpreF (Regimen B) - Respiratory Syncytial Virus (RSV) | Phase 3 | Not yet recruiting | Pfizer | 750 | 2026-10-29 | 2026-10-21 |
| A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss ponsegromab, placebo - Non-small Cell Lung Cancer (NSCLC), Cachexia | Phase 1 | Not yet recruiting | Pfizer | 80 | 2026-10-23 | 2026-09-25 |
| A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments Elranatamab - Relapsed/Refractory Multiple Myeloma, Multiple Myeloma | Phase 4 | Not yet recruiting | Pfizer | 75 | 2026-10-22 | 2026-10-19 |
| A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2) Berobenatide, Placebo - Apnea, Sleep Disorders | Phase 3 | Not yet recruiting | Pfizer | 258 | 2026-10-19 | 2026-10-19 |
| A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity Berobenatide - Overweight and/or Obesity, Healthy Participants | Phase 1 | Not yet recruiting | Pfizer | 144 | 2026-10-16 | 2026-10-15 |
| Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset ABRYSVO - Respiratory Syncytial Virus Infections | Not yet recruiting | Pfizer | 1 | 2026-10-15 | 2026-09-24 | |
| A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity Berobenatide, Placebo - Obesity, Overweight | Phase 3 | Not yet recruiting | Pfizer | 432 | 2026-10-15 | 2026-10-15 |
| Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer PF-08634404, Pembrolizumab, Standard of Care Chemotherapy - Endometrial Neoplasms, Endometrial Cancer | Phase 3 | Not yet recruiting | Pfizer | 600 | 2026-10-09 | 2026-10-08 |
Showing 20 of 4905. Sign in to see all of them.
Breast Neoplasms (282) · Arthritis, Rheumatoid (149) · Carcinoma, Non-Small-Cell Lung (149) · Neoplasms (128) · Carcinoma, Renal Cell (115) · Diabetes Mellitus, Type 2 (113) · COVID-19 (106) · Alzheimer Disease (83) · Pain (80) · Colorectal Neoplasms (79) · Neoplasm Metastasis (76) · HIV Infections (74) · Dermatitis, Atopic (70) · Prostatic Neoplasms (70) · Obesity (69)
Sunitinib (180) · palbociclib (143) · tofacitinib (105) · Axitinib (95) · Varenicline (83) · avelumab (66) · Atorvastatin (64) · talazoparib (61) · Crizotinib (58) · Etanercept (58) · Maraviroc (54) · Azithromycin (53) · Pregabalin (50) · Letrozole (48) · exemestane (47)
United States (2772) · Canada (693) · Spain (594) · Germany (561) · Belgium (532) · United Kingdom (526) · France (478) · Japan (436) · Italy (432) · Poland (400) · Australia (383) · South Korea (380) · Netherlands (269) · China (265) · Czechia (265)
Andrew McGovern, MD (9) · Mirjana Kujacic, MD (6) · Paul Newell, MD (6) · Paul Newell, MBBS, MRCP (5) · Alison L. Hannah, MBBS (4) · Asokumar Buvanendran, MD (4) · Angela DeMichele, MD (3)
PMID 32816215, PMID 37142273, PMID 36931693, PMID 36526796, PMID 34870800, PMID 36600185, PMID 36601090, PMID 33127856, PMID 28143815, PMID 39192350, PMID 25047021, PMID 37994400, PMID 38958913, PMID 27238653, PMID 28410911, PMID 34213819, PMID 37160401, PMID 37917289, PMID 35061234, PMID 37453736, PMID 35164991, PMID 26275429, PMID 30221827, PMID 30936738, PMID 36814062, PMID 37460782, PMID 25577718, PMID 31319851, PMID 33813736, PMID 34921355, PMID 26554876, PMID 30061279, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 32681472, PMID 34611902, PMID 35235189, PMID 38896380, PMID 42162528, PMID 25758058, PMID 28181260, PMID 28304227, PMID 28459966, PMID 28597967, PMID 28941219, PMID 29685591, PMID 29912399
2023 (70), 2014 (65), 2018 (52), 2017 (47), 2008 (42), 2009 (42), 2015 (40), 2025 (40), 2016 (39), 2019 (39), 2005 (6), 2004 (3), P30CA138292 (3), K01DA019446 (2), P30CA060553 (2)